Caixin Global
@caixin
Award-winning journalism from China's most respected newsroom. App:
加入 January 2010
77 正在關注 91K 粉絲
Hong Kong’s securities regulator suspended trading in Cloudbreak Pharma after raising concerns that demand for the ophthalmic-drug developer’s IPO may have been artificially inflated.
顯示更多
